


PHARMACEUTICAL 2023

SCYNEXIS









SCYNEXIS INC

Rank 348 of 446



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 20% points. The greatest weakness of SCYNEXIS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 110% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	79,061
Cost of Goods Sold	0
Intangible Assets	408
Liabilities, Current	17,618
Liabilities, Non-Current	2,921
Other Assets	8,341
Other Compr. Net Income	0
Other Expenses	-4,072
Other Liabilities	64,038
Other Net Income	18,248
Other Revenues	5,091
Property and Equipment	0
Research and Development	27,259
Selling, General and Administrative Expense	62,961

Output Variable	Value in 1000 USD
Assets	87,810
Liabilities	84,577
Expenses	86,148
Revenues	5,091
Stockholders Equity	3,233
Net Income	-62,809
Comprehensive Net Income	-62,809
Economic Capital Ratio	-66%

